Researchers identify genetic abnormalities that drive invasiveness in head and neck cancer
A multi-institutional team of researchers has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy.
Through a series of surprises, we followed clues that focused more and more tightly on specific genetic imbalances and their role in the effects of specific immune components in tumor development.
Webster Cavenee, PhD, Co-Principal Investigator, Distinguished Professor Emeritus, University of California San Diego School of Medicine The genetic abnormalities we identified drive changes in the immune cell composition of the tumors that, in turn, dictates responsiveness to standard of care immune checkpoint inhibitors.
New study on immunotherapy resistance sanantoniopost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sanantoniopost.com Daily Mail and Mail on Sunday newspapers.
Clinical study identifies genetic changes in head-neck cancer, association with immunotherapy resistance
Clinical study identifies genetic changes in head-neck cancer, association with immunotherapy resistance
Last Updated: Tue, Apr 27th, 2021, 10:20:08hrs
Washington [US], April 27 (ANI): A multi-institutional team of researchers has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy. Through a series of surprises, we followed clues that focused more and more tightly on specific genetic imbalances and their role in the effects of specific immune components in tumour development, said co-principal investigator Webster Cavenee, PhD, Distinguished Professor Emeritus at the University of California San Diego School of Medicine.
E-Mail
A multi-institutional team of researchers has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy. Through a series of surprises, we followed clues that focused more and more tightly on specific genetic imbalances and their role in the effects of specific immune components in tumor development, said co-principal investigator Webster Cavenee, PhD, Distinguished Professor Emeritus at University of California San Diego School of Medicine. The genetic abnormalities we identified drive changes in the immune cell composition of the tumors that, in turn, dictates responsiveness to standard of care immune checkpoint inhibitors.